BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Review of Endocrinology & Metabolism 2014;5:403-23. [DOI: 10.1586/eem.10.5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease 2015;47:181-90. [DOI: 10.1016/j.dld.2014.09.020] [Cited by in Crossref: 371] [Cited by in F6Publishing: 346] [Article Influence: 53.0] [Reference Citation Analysis]
2 Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, Romagnoli D, Loria P. Nonalcoholic fatty liver disease and aging: Epidemiology to management. World J Gastroenterol 2014; 20(39): 14185-14204 [PMID: 25339806 DOI: 10.3748/wjg.v20.i39.14185] [Cited by in CrossRef: 143] [Cited by in F6Publishing: 126] [Article Influence: 17.9] [Reference Citation Analysis]
3 Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World J Gastroenterol 2014; 20(23): 7089-7103 [PMID: 24966582 DOI: 10.3748/wjg.v20.i23.7089] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
4 Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Review of Gastroenterology & Hepatology 2015;9:603-27. [DOI: 10.1586/17474124.2015.1007955] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 10.0] [Reference Citation Analysis]
5 Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother. 2011;12:2215-2234. [PMID: 21883025 DOI: 10.1517/14656566.2011.597742] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
6 Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2011;5:253-263. [PMID: 21476920 DOI: 10.1586/egh.11.18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
7 Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J Gastroenterol 2014; 20(28): 9330-9337 [PMID: 25071327 DOI: 10.3748/wjg.v20.i28.9330] [Cited by in F6Publishing: 123] [Reference Citation Analysis]
8 Cardoso BR, Tan SY, Daly RM, Via JD, Georgousopoulou EN, George ES. Intake of Nuts and Seeds Is Associated with a Lower Prevalence of Nonalcoholic Fatty Liver Disease in US Adults: Findings from 2005-2018 NHANES. J Nutr 2021;151:3507-15. [PMID: 34522969 DOI: 10.1093/jn/nxab253] [Reference Citation Analysis]
9 Radwan MM, Radwan BM, Nandipati KC, Hunter WJ, Agrawal DK. Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Expert Rev Clin Immunol. 2013;9:727-738. [PMID: 23971751 DOI: 10.1586/1744666x.2013.816484] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 Ma J, Feng J, Zhou X. Long non-coding RNA HAGLROS regulates lipid metabolism reprogramming in intrahepatic cholangiocarcinoma via the mTOR signaling pathway. Exp Mol Pathol 2020;115:104466. [PMID: 32446859 DOI: 10.1016/j.yexmp.2020.104466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 2011;5:279-89. [PMID: 21476922 DOI: 10.1586/egh.11.19] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]